To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Bionano Genomics (NasdaqCM:BNGO) Q4 2025 Earnings call March 23, 2026 04:30 PM ET Company ParticipantsErik Holmlin - President and CEOMark Adamchak - VP of AccountingWebb Campbell - VPConference Call ParticipantsYi Chen - Managing Director and Senior AnalystOperatorGood day, and welcome to the Bionano fourth quarter and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.W ...

Bionano Genomics (NasdaqCM:BNGO) Q4 2025 Earnings call March 23, 2026 04:30 PM ET Company ParticipantsErik Holmlin - President and CEOMark Adamchak - VP of AccountingWebb Campbell - VPConference Call ParticipantsYi Chen - Managing Director and Senior AnalystOperatorGood day, and welcome to the Bionano Q4 and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.Webb Campbell ...

Bionano Genomics (NasdaqCM:BNGO) Q4 2025 Earnings call March 23, 2026 04:30 PM ET Speaker2Good day, and welcome to the Bionano fourth quarter and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.Speaker3Thank you, Carmen, and good afternoon, everyone. Welcome to Bionano's fourth quarter and full year 2025 financial results conference call. On the call today is Dr. Erik ...

BNGO stock is soaring. See the chart and price action here. Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday’s regular session.The Financials: Narrowing the GapFor the fourth quarter, Bionano reported revenue of $8 million, landing at the high end of its previous guidance. While this was a 3% decrease from the prior year, the real victory was in the margins. Full-year gross margins skyrocketed to 46%, a massive leap from the 1% seen in 2024.The improveme ...

Q4'25 & FY25 Financial Results Webcast & Call March 23, 2026 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM Commission File Number 001-38613 Bionano Genomics, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 26-1756290 | | --- | ...

Conference call today, March 23, 2026, at 4:30 PM ETSAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano. “Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued grow ...

Financial Results - Bionano Genomics, Inc. reported preliminary financial results for Q4 and fiscal year ended December 31, 2025[4] - The report does not include specific financial figures or performance metrics in the provided content[5] - The financial results are not deemed "filed" under the Securities Exchange Act, limiting liability under that section[5] Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol BNGO[2] - The company is classified as an emerging growth company under the Securities Act[3] - R. Erik Holmlin, Ph.D., serves as the President and CEO, acting as the principal executive and financial officer[10] Report Details - The press release detailing these results was issued on January 12, 2026[6] - The report includes an Inline XBRL exhibit for the cover page of the Current Report[6] - The report does not provide details on user data, future outlook, or new product developments[5] - No information on market expansion or mergers and acquisitions is included in the content[5]

Core Viewpoint - Bionano Genomics, Inc. is a life sciences company focused on genome analysis, providing essential tools and services for genetic research, which are vital for understanding genetic diseases and developing treatments [1] Financial Performance - Bionano is set to release its quarterly earnings on March 23, 2026, with Wall Street estimating a loss of $2.47 per share and analysts predicting a smaller loss of $1.40 per share [2][6] - Revenue projections are closely aligned, with Wall Street expecting $7.88 million and analysts estimating $7.85 million, while the company previously projected revenue between $7.8 million and $8.0 million [2] Stock Valuation - The current stock price of Bionano is $1.12, with a negative price-to-earnings (P/E) ratio of -0.16 and a price-to-sales ratio of 0.13, indicating the stock is valued at 13 cents for every dollar of sales [3][6] - The enterprise value to sales ratio is 0.28, reflecting the company's valuation relative to its revenue [3] Financial Health Indicators - The enterprise value to operating cash flow ratio is around -0.43, indicating negative cash flow [4] - The debt-to-equity ratio is 0.15, suggesting low debt levels, while the current ratio of 2.12 indicates good short-term financial health, with more than twice the current assets compared to liabilities [4][6] Analyst Ratings - Analyst Yi Chen from HC Wainwright and Co. maintains a Buy rating on Bionano, although the price target was reduced from $11 to $7 in November 2025 [5] - Bionano will host a conference call and webcast on March 23, 2026, to discuss its financial results and corporate progress, with CEO Erik Holmlin participating [5]